الشهادات العلمية

• 1981

  درجة البكالوريوس من 00طب القصر العيني, القاهرة, القاهرة, مصــــــــر

• 1987

  درجة الماجستير من الأطفالكلية الطب, القاهرة بمصر, القاهرة, مصــــــــر

• 1989

  درجة الدكتوراة من الأدويةالطب, المنيا, المنيا, مصــــــــر

• 1998

  درجة الدكتوراة من الأدوية وقسم الأدوية الكيمياءكلية الطب, جامعة المنيا - جامعة الاباما ب, المنيا, مصــــــــر

الخبرات السابقة

• 1982-1983

  طبيب امتياز, مستشفى قصر العيني ومستشفيات وزارة الصحة, القاهرة, مصــــــــر

• 1983-1984

  طبيب عام, وزارة الدفاع, القاهرة, مصــــــــر

• 1984-1989

  معيد بقسم الأدوية, قسم الأدوية - كلية الطب - جامعة المنيا, المنيا, مصــــــــر

• 1989-1991

  مدرس مساعد بقسم الأدوية, قسم الأدوية - كلية الطب - جامعة المنيا, المنيا, مصــــــــر

• 1991-1996

  باحث ما بعد الدكتوراة, قسم كيميا حيوية الأدوية - جامعة الاباما ببرمنجهام - الولايات المتحدة الأمريكيةا, برمنجهام - الاباما, امــريــكـا

• 1996-1998

  مدرس مساعد بقسم الأدوية, قسم الأدوية - كلية الطب - جامعة المنيا, المنيا, مصــــــــر

• 1998-2003

  مدرس بقسم الأدوية, قسم الأدوية - كلية الطب - جامعة المنيا, المنيا, مصــــــــر

• 2003-2007

  أستاذ مشارك وقائم بعمل رئيس قسم الأدوية, قسم الأدوية - كلية الطب - جامعة المنيا, المنيا, مصــــــــر

• 2007-حاليا

  أستاذ مشارك, كلية الصيدلة جامعة الملك عبد العزيز- جده, جده, المملكة العربية السعودية

• 2012-حاليا

  أستــــــــاذ, قسم الأدوية - كلية الطب - جاتمعة المنيا, المنيا, مصــــــــر

• 2013-حاليا

  أستــــاذ, كلية الصيدلة جامعة الملك عبد العزيز- جده, جده, المملكة العربية السعودية

الاهتمامات البحثية

1. دراسة تأثير الأدوية  أو النواتج الطبيعية على الجهاز الدوري سوا ء على الجسم ككل أو الأعضاء المعزولة خارج الجسم .
2. دراسة تأثير الأدوية أو النواتج الطبيعية على قرحة المعدة المستحدثة بطرق مختلفة في الجرذان .
3. دراسة تأثير الأدوية أو النواتج الطبيعية على مرض السكري المستحدث في الجرذان بطرق مختلفة والوقاية من مضاعفاته .
4. دراسة تأثير أدوية السرطان على الخلايا وكذا سمية هذه الأدويه على الحيوان .
5. دراسة تأثير الأدوية على ضغط العين.
6. دراسة تأثير الأدوية والنواتج الطبيعية على تليف الكبد المستحدث معملياً.

الاهتمامات العلمية

• List of Publications
1. Abdel-Naim AB, Neamatallah T, Eid BG, Esmat A, Alamoudi AJ, Abd El-Aziz GS, Ashour OM. 2-Methoxyestradiol Attenuates Testosterone-Induced Benign Prostate Hyperplasia in Rats through Inhibition of HIF-1α/TGF-β/Smad2 Axis. Oxid Med Cell Longev 2018, 2018, Article ID 4389484, 12 pages.
2. Al-Abd AM, Alamoudi AJ, Abdel-Naim AB, Neamatallah TA, Ashour OM. Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies - A review. J Adv Res. 2017; 8(6): 591-605.
3. Algandaby MM, Breika RM, Eid BG, Neamatallah TA, Abdel-Naim AB, Ashour OM. Icariin protects against thioacetamide-induced liver fibrosis in rats: Implication of anti-angiogenic and anti-autophagic properties. Pharmacol Rep 2017; 69(4): 616-24.
4. Algandaby MM, Al-Sawahli MM, Ahmed OAA, Fahmy UA, Abdallah HM, Hattori M, Ashour OM, Abdel-Naim AB. Curcumin-zein nanospheres improve liver targeting and antifibrotic activity of curcumin in carbon tetrachloride-induced mice liver fibrosis. J Biomed Nanotechnol 2016; 12(9): 1746-57.
5. Algandaby MM, El-Halawany AM, Abdallah HM, Alahdal AM, Nagy AA, Ashour OM, Abdel-Naim AB. Gingerol protects against experimental liver fibrosis in rats via suppression of pro-inflammatory and profibrogenic mediators. Naunyn Schmiedebergs Arch Pharmacol. 2016; 389(4): 419-28.
6. Aly HA, El-Shitany NA, El-Beshbishy HA, Ashour OM. Ameliorative effect of lycopene against 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced rat liver microsomal toxicity: An in vitro study. Toxicol Ind Health 2015; 31(10): 938-50.
7. Abdallah HM, Abdel-Naim AB, Ashour OM, Shehata IA, Abdel-Sattar EA. Anti-inflammatory activity of selected plants from Saudi Arabia. Z Naturforsch C 2014; 69: 1-9.
8. Abdallah HM, Mohamed MA, Abdou AM, Hamed MM, Abdel-Naim AB, Ashour OM. Protective effect of Centaurea pallescens Del. against CCl₄-induced injury on a human hepatoma cell line (Huh7). Med Chem Res 2013; 22; 5700-5706.
9. Elberry AA, Refaie SM, Kamel M, Ali T, Darwish H, Ashour OM. Oxytocin ameliorates cisplatin-induced nephrotoxicity in Wistar rats. Ann Saudi Med 2013; 33(1): 57-62.
10. Ashour OM, Abdel-Naim AB, Abdallah HM, Nagy AA, Mohamadin AM, Abdel-Sattar EA. Evaluation of the potential cardioprotective activity of some Saudi plants against doxorubicin toxicity. Z Naturforsch C 2012; 67(5-6): 297-307.
11. Abdel-Sattar E, El-Gayed SH, Shehata I, Ashour OM, Nagy AA, Mohamadin AM. Antioxidant and cardioprotective activity of Stachys schemperi vatke against doxorubicin-induced cardiotoxicity. Bulletin of Faculty of Pharmacy, Cairo University 2012; 50: 41-47.
12. Ibrahim SA, Ashour OM, Abdel Zahir WY, El-Bitar HI. Potential interactions between glimepiride and candesartan in alloxan-induced diabetic rats. J Egypt Soc Toxicol 2012; 45: 21-30.
13. Elberry AA, Mufti ST, Al-Maghrabi JA, Abdel-Sattar EA, Ashour OM, Ghareib SA, Mosli HA. Anti-inflammatory and antiproliferative activities of date palm pollen (Phoenix dactylifera) on experimentally-induced atypical prostatic hyperplasia in rats. J Inflamm (Lond) 2011; 8(1): 40.
14. Ibrahim MY, Ashour OM. Changes in nitric oxide and free radicals levels in rat gastrocnemius muscle during contraction and fatigue. Clin Exp Pharmacol Physiol 2011; 38: 791-795.
15. Ashour OM, Elberry AA, Alahdal AM, Al Mohamadi AM, Nagy AA, Abdel-Naim AB, Abdel-Sattar EA, Mohamadin AM. Protective effect of bilberry (Vaccinium myrtillus) against doxorubicin-induced oxidative cardiotoxicity in rats. Med Sci Monit 2011; 17(4): BR110-115.
16. Algandaby MM, Alghamdi HA, Ashour OM, Abdel-Naim AB, Ghareib SA, Abdel-Sattar EA, Hajar AS. Mechanisms of the antihyperglycemic activity of Retama raetam in streptozotocin-induced diabetic rats. Food Chem Toxicol 2010; 48(8-9): 2448-2453.
17. Elberry AA, Abdel-Naim AB, Abdel-Sattar EA, Nagy AA, Mosli HA, Mohamadin AM, Ashour OM. Cranberry (Vaccinium macrocarpon) protects against doxorubicin-induced cardiotoxicity in rats. Food Chem Toxicol 2010; 48(5): 1178-1184.
18. Morsy MA, Ashour OM, Fouad AA, Abdel-Gaber SA. Gastroprotective effects of the insulin sensitizers, rosiglitazone and metformin, in indomethacin-induced gastric ulcer in type 2 diabetic rats. Clin Exp Pharmacol Physiol 2010; 37(2): 173-177.
19. Ibrahim MA, Ashour OM, Ibrahim YF, El-Bitar HI, Gomaa W, Abdel-Rahim SR. Angiotensin-converting enzyme inhibition and angiotensin AT(1)-receptor antagonism equally improve doxorubicin-induced cardiotoxicity and nephrotoxicity. Pharmacol Res 2009; 60(5): 373-381.
20. Ashour OM, Sawan AS. Celecoxib toxicity on rats' thyroid gland. El-Minia Med Bul 2009; 20(1): 26-37.
21. Morsy M, Ashour O, Amin E, Rofaeil R. Gastroprotective effects of telmisartan on experimentally-induced gastric ulcers in rats. Pharmazie 2009; 64(9): 590-594.
22. Mohamadin AM, Ashour OM, El-Sherbeny NA, Alahdal AM, Morsy GM, Abdel-Naim AB. Melatonin protects against hydrogen peroxide-induced gastric injury in rats. Clin Exp Pharmacol Physiol 2009; 36(4): 367-372.
23. Ashour OM, Khalifa MMA, Abdelrahman AM, Geddawy AIM. Modulation of the pathogenesis of diabetic vascular complications by antioxidants in streptozotocin-induced diabetes in rats. El-Minia Med Bul 2008; 19(1): 238-254.
24. Ashour OM, Fouad AA, Kamel MY, El-Bitar HI. Therapeutic potential of vitamin E and Panax ginseng in experimentally-induced Alzheimer's disease model in rabbits. Alex J Pharm Sci 2007; 21(2): 87-92.
25. Ismail HA, Khalifa MM, Hassan MK, Ashour OM. Insights in the mechanisms underlying the anti-ulcer activity of nicorandil. Pharmazie 2007; 62(1): 60-66.
26. Ismail HA, Khalifa MM, Hassan MK, Ashour OM. Investigation of the mechanisms underlying the gastroprotective effect of nicorandil. Pharmacology 2007; 79: 76-85.
27. Khalifa MMA, Ashour OM, Abdelrahman AM, Fouad AA, Amin EF. Evaluation of systemic effects of ophthalmic instillation of timolol, betaxolol and carteolol for six weeks in rabbits. Alex J Pharm Sci 2006; 20(2): 137-141.
28. El-Sayed S E-D, Ashour OM. Possible interaction between nitric oxide modulators and calcium channel blockers in indomethacin-induced gastric ulcer in rats. Bull Egypt Soc Physiol Sci 2005; 25(2): 359-378.
29. Abdelrahman AM, Fouad AA, Ashour OM. Effect of intravenous anesthetics on endothelium-dependent vasodilatation in intact rats. Bull Alex Fac Med 2002; 38(1): 107-111.
30. Abdel-Ali SA, Ashour OM, Abdel-Haleem, A-B TA. Possible interactions between gentamicin, cefotaxime, ofloxacin and metronidazole with some non-depolarizing neuromuscular blocking drugs on rat phrenic nerve-hemidiaphragm preparation. Al-Azhar Med J 2002; 31(3&4): 394-405.
31. Khalifa MMA, Hassan MKA, Ashour OM, Heeba GH. Evaluation of the anti-ulcer activity of pibutidine hydrochloride (IT-066); the new histamine H₂-receptor antagonist, in cold-restraint stress- and ethanol-induced ulcer models in rats. Al-Azhar Med J 2002; 31(1): 33-47.
32. Rizk HA, Ashour OM. Rapid colorimetric methods for determining drugs resistance of Mycobacterium tuberculosis in liquid medium. Egypt J Med Microbiol 2001; 10(4): 781-788.
33. Ashour OM, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH. Effect of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on plasma concentration of uridine released from 2^¢,3^¢,5^¢-tri-O-acetyluridine, a prodrug of uridine: relevance to uridine rescue in chemotherapy. Cancer Chemother Pharmacol 2000; 46(3): 235-240.
34. Ashour OM, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH. Effect of administration of 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase, on the antitumor efficacy of 5-fluoro-2^¢-deoxyuridine against murine colon tumor C26-10. Biochem Pharmacol 2000; 60(5): 687-692.
35. Ashour OM, Naguib FN, Panzica RP, Al Safarjalani ON, el Kouni MH. Modulation of 5-fluorouracil host toxicity by 5-(benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2^¢,3^¢,5^¢-tri-O-acetyluridine, a prodrug of uridine. Biochem Pharmacol 2000; 60(3): 427-431.
36. Ashour OM, Al Safarjalani ON, Naguib FN, Goudgaon NM, Schinazi RF, el Kouni MH. Modulation of plasma uridine concentration by 5-(phenylselenenyl)acyclouridine, an inhibitor of uridine phosphorylase: Relevance to chemotherapy. Cancer Chemother Pharmacol 2000; 45(5): 351-361.
37. Abdel-Hakim SM, Ashour OM. Differential protective effect of melatonin against experimentally-induced gastric mucosal injury in rats. Bull Egypt Soc Physiol Sci 1999; 19(1): 168-179.
38. Ibrahim IY, Abdel-Hakim SM, Hassan MKA, Ashour OM. Effect of modulation of nitric oxide and prostaglandin synthesis on the development of experimental gastric ulcers in rats. Bull Egypt Soc Physiol Sci 1999; 19(1): 151-166.
39. Khalifa MMA, Hassan MKA, Ashour OM, Abdel-Haleem A-B TA. Lipid peroxidation and atherosclerosis: Effect of calcium channel blockers and angiotensin converting enzyme inhibitors. J Egypt Soc Toxicol 1999; 21: 1-8.
40. Ashour OM, Abdel-Hakim SM, Abdel-Hafiz HM. Effect of the alkali metals; lithium, cesium and rubidium, on serum glucose level and the role of adrenoceptor antagonism in modulating such effects in male albino rats. Al-Azhar Med J 1998; 27(3,4): 571-585.
41. Ashour OM, Khalifa MMA, Abdel-Raheem MH, el Kouni MH. Evaluation of 5-(phenylselenenyl)acyclouridine (PSAU), a novel uridine phosphorylase inhibitor. Assiut Med J 1997; 21: 31-55.
42. Ashour OM, Naguib FNM, el Kouni MH. 5-(m-benzyloxybenzyl)barbituric acid acyclonucleoside, a uridine phosphorylase inhibitor and 2^¢,3^¢,5^¢-triacetyluridine, a prodrug of uridine, as modulators of plasma uridine concentration. Biochem Pharmacol 1996; 51: 1601-1611.
43. Sommadossi J-P, Cretton EM, Kidd LB, McClure HM, Anderson DC, el Kouni MH. Effects of 5-benzylacyclouridine, an inhibitor of uridine phosphorylase, on the pharmacokinetics of uridine in rhesus monkeys: implications for chemotherapy. Cancer Chemother Pharmacol 1995; 37: 14-22. (Acknowledged)
44. Ashour OM, Naguib FN, Khalifa MM, Abdel-Raheem MH, Panzica RP, el Kouni MH. Enhancement of 5-fluoro-2^¢-deoxyuridine antitumor efficacy by the uridine phosphorylase inhibitor 5-(benzyloxybenzyl)barbituric acid acyclonucleoside. Cancer Res 1995; 55(5): 1092-1098.
45. Naguib FNM, Ashour OM, Schinazi RF, MMA, Abdel-Raheem MH, el Kouni MH. Effect of 5(phenylselenenyl)acyclouridine (PSAU) on plasma uridine concentration in female CD-1 mice. FASEB J 1994; 8: A95 (553). [Abstract]
46. Ashour OM, Naguib FNM, Khalifa MMA, Abdel-Raheem MH, el Kouni MH. Inhibition constants of 5-(benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA) for hepatic uridine phosphorylase (UrdPase) from different species. FASEB J 1994; 8: A95 (552). [Abstract]
47. Naguib FNM, Levesque DL, Wang E-C, Panzica RP, el Kouni MH. 5-benzylbarbituric acid derivatives, potent and specific inhibitors of uridine phosphorylase. Biochem Pharmacol 1993; 46(7): 1273-1283. (Acknowledged)
48. Ashour OM, Guarcello V, Khalifa MMA, Abdel-Raheem MH, Naguib FNM, Panzica RP, el Kouni MH. Elevation of plasma uridine by the uridine phosphorylase (UrdPase) inhibitor 5- (benzyloxybenzyl)barbituric acid acyclonucleoside (BBBA) in mice. Pharmacologist 1993; 35: 365.
49. Ashour OM, Abdel-Raheem MH, El-Bitar HIA. Some possible (cardiovascular) interactions between ketamine HCl and pancuronium Br. Annual conference of the Egyptian Society of Pharmacology and Experimental Therapeutics; 1989.

المواد والمحاضرات

مجالات الخبرة